TORONTO -- (MARKET WIRE) -- 08/09/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that it will be exhibiting at the American Association of Diabetes Educators (www.aadenet.org) 33rd Annual Meeting & Exhibition, August 10 - 12, 2006 at the Los Angeles Convention Center.

For the first time, Generex is exhibiting at the convention, with a presence in Booth 112 in the Los Angeles Convention Center where it will demonstrate its proprietary technologies for the development of products that will help patients with diabetes control and manage the disease. Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs and a former President of the American Diabetes Association, will be present at the Generex booth to discuss the Company's products.

The American Association of Diabetes Educators is a multidisciplinary professional membership organization of healthcare professionals dedicated to integrating successful self-management as a key outcome in the care of people with diabetes and related conditions. Diabetes education, also called diabetes self-management training, gives people with diabetes the knowledge, skills, and tools they need to successfully manage their diabetes and avoid many of the complications associated with the disease.

The 100+ educational sessions at the conference will offer attendees the latest information on diabetes self-management training and care and the Exhibit Hall will enhance the learning experience with hands-on product introductions and information.

"We consider this conference to be an ideal forum for the exhibition of the Generex diabetes products, including its flagship product, Generex Oral-lyn(TM), and its complementary over-the-counter diabetes management products," said Anna Gluskin, the Company's President & Chief Executive Officer. "The AADE represents a focused audience responsible for training people who live with diabetes on the various diabetes products available to improve their quality of life."

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contacts:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: (800) 391-6755
or (416) 364-2551

Andrew Hellman
CEOcast, Inc.
Phone: (212) 732-4300

Dolores Naney
Rubenstein Public Relations
Phone: (212) 843-8018
Email Contact